TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
In the INTerpath-001 trial, adding the individualized mRNA vaccine intismeran autogene to pembrolizumab was associated with higher two-year recurrence-free survival than pembrolizumab alone after melanoma surgery. Overall survival benefit has not been demonstrated, and researchers still need to establish which patients benefit, how vaccination should fit with other treatments, and whether results extend beyond melanoma.
An individualized mRNA cancer vaccine added to pembrolizumab was associated with better two-year recurrence-free survival in a phase III trial of patients with resected melanoma, but an overall survival benefit has not been demonstrated. The findings support further study of the approach while leaving open who benefits, when to give the vaccine and whether it works in other cancers.
In INTerpath-001, 1,137 patients with completely resected stage IIB to IV melanoma were randomly assigned to receive pembrolizumab with either intismeran autogene, an individualized mRNA vaccine, or placebo. Results presented at ESMO showed two-year recurrence-free survival of 82.2% in the vaccine group and 70% in the placebo group, an absolute difference of 12.2 percentage points. The reported hazard ratio was 0.58, with a 95% confidence interval of 0.45 to 0.75.
At a median follow-up of 24.6 months, the trial had not demonstrated an overall survival benefit. The recurrence-free survival result means fewer patients in the vaccine group had experienced recurrence or another event counted by the trial’s measure during the follow-up period; it does not establish that vaccination prevents recurrence for every patient or improves survival over a longer period.
Vaccine production succeeded for more than 99% of patients assigned to intismeran, according to the report. Median time to the first vaccine dose was 64 days. Grade 3-5 treatment-related adverse events occurred in 14.2% of the vaccine-plus-pembrolizumab group and 13.4% of the pembrolizumab-only group. However, all-cause adverse events led to discontinuation of any study drug in 16.6% and 9.5%, respectively, showing that similar rates of severe treatment-related events do not mean the overall treatment burden was identical.
A Recurrence Benefit, Not Yet a Survival Result
For people who have had melanoma removed, a recurrence can mean further treatment and additional health burdens. A treatment that reduces recurrence could therefore matter even before evidence of longer survival is available. The trial’s 12.2-percentage-point difference in two-year recurrence-free survival is a meaningful signal, but patients and clinicians need to weigh it against treatment burden and uncertainty about lasting benefit.
The result also comes as melanoma care grows more complex. Decisions about surgery, checkpoint inhibitors and postoperative treatment are changing as evidence develops. Adding a personalized vaccine raises practical questions about which patients are most likely to benefit and how to fit vaccine production and dosing into care. The trial tests adding the vaccine to pembrolizumab; because it did not include a vaccine-only group, it cannot formally establish that the two treatments act synergistically.
Products Worth Considering
Fitbit Versa 2 Health and Fitness Smartwatch with Heart Rate, Alexa, Music, Sleep and Swim Tracking
LEVOIT Air Purifier for Home, Pets, Bedroom, Smart WiFi
Bowflex SelectTech 840 Adjustable Kettlebell
As an affiliate, we earn on qualifying purchases.
Melanoma Care Is Changing Before Surgery
Individualized mRNA vaccines are designed using a patient’s tumor information to select predicted neoantigens — targets that may prompt an immune response. Antigen-presenting cells process the vaccine’s instructions, while pembrolizumab blocks PD-1 signaling, which can limit T-cell activity. This provides a biological rationale for combining the treatments, but a predicted target does not necessarily generate an effective response against the cancer cells that could cause recurrence.
Other studies have shifted attention toward neoadjuvant immunotherapy, given before surgery. The source report cites SWOG S1801, in which starting pembrolizumab before surgery improved event-free survival compared with giving it entirely afterward, and NADINA, which reported improved event-free survival with neoadjuvant nivolumab-ipilimumab followed by surgery and response-directed postoperative treatment, compared with surgery followed by nivolumab. These separate trials do not establish how those strategies compare with vaccination; their populations and treatment designs differ.
Evidence outside melanoma is early. A small phase I pancreatic cancer study found persistent vaccine-induced T-cell responses in some patients given an individualized mRNA vaccine with atezolizumab and chemotherapy. Immune responders had longer recurrence-free survival than nonresponders. That finding indicates biological activity, not proof of improved outcomes: the study was small, had no randomized control group and compared patients based on their immune response.
Survival, Selection and Treatment Timing
Longer-term outcomes remain unknown. The reported median follow-up was 24.6 months, and an overall survival benefit had not been demonstrated. The results also do not show that all patients benefit, or identify which patient or tumor features predict benefit from vaccination.
The best place for vaccination in treatment is unsettled. INTerpath-001 does not answer whether a vaccine should be given before or after surgery, how it should be sequenced with neoadjuvant immunotherapy, or whether patients with a strong response to treatment might avoid additional therapy. Researchers also need to test whether biomarkers such as pathological response or circulating tumor DNA can guide treatment: identifying higher recurrence risk is not the same as identifying patients more likely to benefit from a vaccine.
It is also unclear whether the melanoma results apply to other cancers. Tumors differ in the availability of immune targets and in how they present those targets or suppress immune activity. The pancreatic cancer findings cited in the report are preliminary, not evidence that vaccination improves survival or recurrence outcomes in that disease.
Trials Must Test Who Benefits
Further studies need to follow patients for longer and assess durable outcomes, quality of life and treatment delivery, alongside recurrence and safety. Research should evaluate how personalized vaccines fit with neoadjuvant and postoperative immunotherapy rather than simply adding treatments without clarifying their sequence or value.
Randomized trials are needed to test vaccine combinations in cancers beyond melanoma. The source report notes that a randomized trial is evaluating the vaccine approach in pancreatic cancer more rigorously. Until those data emerge, the melanoma result supports continued investigation, but does not establish a standard approach for other cancers. Regulators will also need to evaluate manufacturing consistency alongside efficacy and safety.
Key Questions
What did the melanoma vaccine trial find?
In INTerpath-001, two-year recurrence-free survival was 82.2% with intismeran autogene plus pembrolizumab, compared with 70% with placebo plus pembrolizumab. The trial enrolled 1,137 patients with completely resected stage IIB to IV melanoma.
Has the vaccine been shown to extend overall survival?
An overall survival benefit had not been demonstrated at the reported median follow-up of 24.6 months. Longer follow-up is needed to understand whether the recurrence-free survival difference translates into longer life.
Does the result prove the vaccine works for other cancers?
No. The phase III result described here is from a melanoma trial. Early pancreatic cancer research has reported vaccine-induced immune responses, but that small, nonrandomized study does not establish improved clinical outcomes.
How is the vaccine combined with pembrolizumab?
The individualized mRNA vaccine is designed to prompt immune responses against predicted tumor-specific targets. Pembrolizumab blocks PD-1 signaling that can limit T-cell activity. INTerpath-001 found a benefit from adding vaccination to pembrolizumab, but had no vaccine-only group to formally test whether the treatments act synergistically.
What questions do researchers still need to answer?
Studies must clarify which patients benefit, the best treatment sequence, long-term outcomes and how to use biomarkers to guide decisions. Researchers also need to establish whether results extend beyond melanoma and how vaccine production affects treatment timing.
Source: medpagetoday.com
